Recent Updates
Recently added Catalysts

COSCIENS Biopharma Inc.

CSCI
Pharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$2.72
▼ -0.24 · -8.11%

Last traded Sep 3, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CSCI financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.9652W HIGH $4.61
Volume
58.61 K
Value Traded
154.81 K
Short % Float
0.62%
-15%Week
-33.17%1 Month
-27.08%3 Month
0%6 Month
+580%5 Year
-75.27%All Time

Cash Data

Unlock CSCI cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.56 M
EPS (TTM)
-6.15
P/E Ratio
-
Ent. Value
1.47 M
Total Shares
3.15 M
Float Shares
3.10 M
Insiders
1.48%
Institutions
9.04%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every CSCI catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CSCI Catalyst Timeline

Dated clinical, regulatory and corporate events for COSCIENS Biopharma Inc.

Unlock the full CSCI catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CSCI actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-09-30Avenanthramides Tablets Phase 2 data readout Phase 2
Unlock 2 more CSCI historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D38 / 100
Pipeline Score
$8M
Pipeline Value
Not rated
Valuation Signal
2
Drugs Scored
-
rNPV / MCap
COSCIENS Biopharma Inc. faces pipeline headwinds (38/100), with $1.9B risk-adjusted pipeline value, led by Macimorelin in Growth Hormone Deficiency (Phase 3).
Showing 0 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the CSCI pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CSCI program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
avenanthramides inflammationPhase 1/2a2025-03-13No significant adverse events were reported during the Phase 1 portion of the AvenActive study. A total of 72 healthy subjects have completed the Phase 1 portion of the AvenActive study which included 48 healthy subjects in a single ascending dose (SAD) arms and 24 healthy subjects in multiple ascending dose (MAD) arms. Subjects received doses ranging from 30 mg to 960 mg per group per day.Read MoreCOSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory ProductRead More
Scroll for more · summaries link to the source press release
Unlock every CSCI trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CSCI insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full CSCI insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in CSCI

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in CSCI for Q2 2026.
Unlock every fund holding CSCI
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CSCI
Shares held by hedge funds each quarter, and who bought or sold.

CSCI Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CSCI option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CSCI option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CSCI options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CSCI ranks across every disease it competes in

Competitive Position is a premium feature
See how CSCI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CSCI News

About COSCIENS Biopharma Inc.

Founded2000
BIOPHARMAWATCH ELITE PLUS
Trade the next CSCI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime